Combination therapy for intermediate-to-high-risk rhabdomyosarcoma
Part of Cancer clinical trials.
This trial tests whether adding all-trans retinoic acid to a standard chemotherapy regimen (VAC) can improve outcomes for people with intermediate-to-high-risk rhabdomyosarcoma. It is for those who have not had prior cancer drug treatment and have adequate organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 60 years old.
- You have a confirmed diagnosis of medium-to-high-risk rhabdomyosarcoma (not the pleomorphic type).
- Your overall health is good (ECOG score 0 or 1, meaning you are fully active or able to do light work).
- You have not received any prior cancer drug treatment (chemotherapy, targeted therapy, etc.).
- Your blood counts, liver, kidney, and clotting function are within certain safe limits.
- You are willing to use effective birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different treatment plans for children with rhabdomyosarcoma based on their individual risk factors. It aims to find the best therapy for each child, potentially improving outcomes.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
This trial tests if adding the immunotherapy drug Pucotenlimab to standard chemotherapy is safe and effective for children and teens with a type of muscle cancer (rhabdomyosarcoma) that is hard to treat. It may offer a new option for patients whose tumors are difficult to remove with surgery alone.
This trial tests a combination of three drugs (tretinoin, azacitidine, and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who have not yet received chemotherapy. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of three drugs—mitoxantrone liposome, cytarabine, and venetoclax—for people with AML that has come back or not responded to standard treatment. It aims to see if this combination is safe and effective.
Hear when a new Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.